30 closest matches · ranked by relevance
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Recurrent Non-small Cell Lung Cancer · Squamous Cell Lung Cancer · Stage III Non-small Cell Lung Cancer
Primary: 6-month Progression Free Survival (PFS) Rate Within the Entire FGFR1 Amplified Group — 0 percentage of participants
Lung Cancer
Primary: Overall Clinical Response Rate — 17 Percentage of participants
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria — 0; 9; 6; 6 Participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.7; 4.2 months
Recurrent Non-small Cell Lung Cancer
Primary: Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts…
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
NSCLC Stage IV
Primary: Objective Response Rate (ORR) — 6 Participants
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Lung Cancer
Primary: Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease — 4.7…
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Non-Small Cell Lung Cancer
Primary: Time to Disease Progression — 4.6; 6.0; 4.1 months — p=0.40
Lung Cancer
Primary: Objective Response Rate (CR + PR by RECIST) Paclitaxel, Pemetrexed, and Bevacizumab in Patients With Advanced Non-Small Lung Cancer Who Have Received no Prior Treatment…
Carcinoma, Non-Small Cell Lung
Primary: Progression-Free Survival (PFS) — 8.0; 8.1; 7.1 months — p=0.3037
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment. — 2 percentage of participants
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 3.1; 1.9 months
Non-Small Cell Lung Cancer
Primary: To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only — 6.3; 11.9 months
Non-small Cell Lung Cancer
Primary: Presence or Absence of a Dose Limiting Toxicity (DLT) of ALT-803 in Combination With Nivolumab — 3; 3; 6; 8 Participants
Lung Cancer
Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561
Lung Cancer
Primary: Overall Response Rate — 26 Percentage of participants
Lung Cancer
Primary: Objective Response Rate (ORR), Presented in Numbers of Participants — 0; 0; 1; 1 Participants
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage